{"id":"adalimumab-etanercept-infliximab","safety":{"commonSideEffects":[{"rate":"5–15%","effect":"Infections (including serious infections)"},{"rate":"10–20%","effect":"Injection site reactions"},{"rate":"5–10%","effect":"Upper respiratory tract infection"},{"rate":"5–10%","effect":"Headache"},{"rate":"<1%","effect":"Tuberculosis reactivation"},{"rate":"low but increased","effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab, etanercept, and infliximab are three distinct TNF-alpha inhibitors used to suppress excessive TNF-alpha signaling in autoimmune and inflammatory conditions. Adalimumab is a fully human monoclonal antibody; etanercept is a TNF receptor fusion protein; infliximab is a chimeric monoclonal antibody. All three reduce TNF-alpha-driven inflammation and immune activation.","oneSentence":"These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:06.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT03839862","phase":"","title":"Faecal Analyses in Spondyloarthritis Therapy","status":"RECRUITING","sponsor":"Region Skane","startDate":"2019-01-01","conditions":"Spondyloarthropathies, Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT01793519","phase":"PHASE4","title":"Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-01","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT01219257","phase":"","title":"Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2011-09","conditions":"Spondyloarthritis, Ultrasonography","enrollment":50},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT04399382","phase":"","title":"A Clinical Study to Evaluate the Efficacy of Biologics in SpA","status":"UNKNOWN","sponsor":"The University of Hong Kong-Shenzhen Hospital","startDate":"2022-01-12","conditions":"Spondyloarthritis (SpA)","enrollment":40},{"nctId":"NCT05379049","phase":"","title":"Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.","status":"UNKNOWN","sponsor":"University of Sulaimani","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Ankylosing Spondylitis","enrollment":80},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT02075697","phase":"","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","startDate":"2008-10","conditions":"Psoriasis","enrollment":3500},{"nctId":"NCT04772248","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-22","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT01610947","phase":"NA","title":"Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2012-05-14","conditions":"Spondyloarthritis","enrollment":398},{"nctId":"NCT01602302","phase":"PHASE4","title":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT02353780","phase":"PHASE4","title":"Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept","status":"TERMINATED","sponsor":"Dr. Larry W. Moreland","startDate":"2015-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":10},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT02778789","phase":"","title":"Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2015-10","conditions":"Rheumatoid Arthritis","enrollment":66},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02242474","phase":"PHASE4","title":"Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":660},{"nctId":"NCT03496831","phase":"","title":"Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs","status":"COMPLETED","sponsor":"Simon Krabbe","startDate":"2006-01-01","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":7500},{"nctId":"NCT03352622","phase":"NA","title":"Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Universidad de Antioquia","startDate":"2017-10-17","conditions":"Pharmacological Action","enrollment":372},{"nctId":"NCT01812954","phase":"","title":"Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis","status":"COMPLETED","sponsor":"Jochen Schmitt.","startDate":"2013-03","conditions":"Psoriasis","enrollment":1},{"nctId":"NCT01691014","phase":"","title":"Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":79},{"nctId":"NCT02116504","phase":"NA","title":"Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-04","conditions":"Rheumatoid Arthritis, Juvenile Idiopathic Arthritis","enrollment":156},{"nctId":"NCT01295151","phase":"PHASE4","title":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":122},{"nctId":"NCT02122406","phase":"","title":"Depression and Anxiety in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2014-01","conditions":"Rheumatoid Arthritis, Depression, Anxiety","enrollment":200},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01592292","phase":"","title":"An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01981473","phase":"","title":"Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":605},{"nctId":"NCT01783015","phase":"PHASE4","title":"Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01356758","phase":"","title":"Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-03","conditions":"Psoriasis, Atopic Dermatitis, Atherosclerosis","enrollment":126},{"nctId":"NCT01604629","phase":"PHASE4","title":"Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF","status":"COMPLETED","sponsor":"Spanish Clinical Pharmacology Society","startDate":"2012-07","conditions":"Spondylarthropathies","enrollment":120},{"nctId":"NCT00726804","phase":"PHASE4","title":"Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis","status":"TERMINATED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2008-03","conditions":"SPONDYLOARTHRITIS","enrollment":7},{"nctId":"NCT02528292","phase":"","title":"Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Barts & The London NHS Trust","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT00724672","phase":"","title":"A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT02376478","phase":"","title":"On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-12","conditions":"Psoriasis, Inflammatory Bowel Diseases","enrollment":222},{"nctId":"NCT01233583","phase":"","title":"Regulatory T-cells in Psoriasis Patients as Targets for Therapy","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2010-06","conditions":"Psoriasis","enrollment":38},{"nctId":"NCT00967538","phase":"PHASE4","title":"Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2009-09","conditions":"Psoriasis","enrollment":89},{"nctId":"NCT02132234","phase":"PHASE4","title":"Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Jagiellonian University","startDate":"2013-06","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT00714493","phase":"PHASE4","title":"RESTART C0168Z05 Rheumatoid Arthritis Study","status":"COMPLETED","sponsor":"Centocor Ortho Biotech Services, L.L.C.","startDate":"2008-07","conditions":"Rheumatoid Arthritis","enrollment":203},{"nctId":"NCT01072058","phase":"PHASE4","title":"Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2008-02","conditions":"Arthritis, Rheumatoid, Spondylitis, Ankylosing","enrollment":100},{"nctId":"NCT01692899","phase":"","title":"Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":780},{"nctId":"NCT01657513","phase":"NA","title":"TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis","status":"UNKNOWN","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2012-06","conditions":"Psoriasis","enrollment":60},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT01166620","phase":"","title":"Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-06","conditions":"Rheumatoid Arthritis","enrollment":4000},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT01083160","phase":"","title":"Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use","status":"TERMINATED","sponsor":"Abbott","startDate":"2008-04","conditions":"Rheumatoid Arthritis","enrollment":82},{"nctId":"NCT01436019","phase":"","title":"Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis","status":"UNKNOWN","sponsor":"Blood Transfusion Centre of Slovenia","startDate":"2011-10","conditions":"Juvenile Idiopathic Arthritis","enrollment":100},{"nctId":"NCT01137838","phase":"","title":"Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":1810},{"nctId":"NCT01237262","phase":"PHASE4","title":"Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2010-11","conditions":"Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.","enrollment":20},{"nctId":"NCT00133315","phase":"PHASE4","title":"TNFalfa Blocking Treatment of Spondylarthropathies","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2004-09","conditions":"Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Adalimumab, etanercept, infliximab","genericName":"Adalimumab, etanercept, infliximab","companyName":"University of Padova","companyId":"university-of-padova","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}